IAMI Trial
Research type
Research Study
Full title
Influenza vaccination After Myocardial Infarction (IAMI trial). A multicenter, prospective, randomized controlled clinical trial based on the Swedish angiography and angioplasty registry (SCAAR) platform
IRAS ID
232487
Contact name
Keith Oldroyd
Contact email
Sponsor organisation
Örebro University Hospital
Eudract number
2014-001354-42
Clinicaltrials.gov Identifier
Duration of Study in the UK
0 years, 6 months, 2 days
Research summary
Research Summary
The IAMI study is a multicentre, prospective, randomised registry-based controlled clinical trial to compare the efficacy of influenza vaccination and placebo in reducing future major adverse cardiac and cerebrovascular events in patients who have had a myocardial infarction.
Summary of Results
In the IAMI trial with more than 2500 patients hospitalised with acute myocardial infarction (MI) or — in fewer than 1% of cases — high-risk stable coronary heart disease, half the participants were assigned to receive the year's standard influenza vaccine and the other half a saline placebo within 72 hours of admission or a revascularisation procedure.
Vaccinated patients experienced a 28% decline in risk for the primary endpoint of death, nonfatal MI, or stent thrombosis over the following year, compared with the control group. Their all-cause mortality dropped 41%, as did their cardiovascular mortality. Their MI risk, however, was not significantly different from that of the control cohort; the rates were both less than 3%.
REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
17/EM/0291
Date of REC Opinion
4 Sep 2017
REC opinion
Further Information Favourable Opinion